This website uses cookies

This websites contains videos from YouTube. This company uses cookies (third party cookies). If you do not want them to use these cookies, you can indicate so here. However, this does mean that you will not be able to watch videos on this website. We also make use of our own cookies in order to improve our website. We don't share our data with other parties. Which cookies are involved?

This website uses cookies to enable video and to improve the user experience. If you do not want to accept these cookies, indicate so here. Which cookies are involved?

Ga direct naar de inhoud, het hoofdmenu, het servicemenu of het zoekveld.

Co-workers

Bussel.JPG

Mark van Bussel, MSc

Ph.D. Student

Experience

In 2013 I finished my Master in Pharmacy at Utrecht University. In my master research project I studied the pleiotropic effects of statins and ACE-inhibitors in patients with COPD at The University of Alabama at Birmingham, United States. Thereafter, I worked as a pharmacist in a hospital pharmacy. My projects focus on phase I/II clinical studies.

Close this window
Geenen, Jill

Jill Geenen, MSc, M.D.

Ph.D. Student

Experience

In 2012 I finished medical school at the University of Amsterdam cum laude. During medical school I did an internship oncology at the NKI. The first year after graduating I worked as a resident of internal medicine in Flevo Hospital. Hereafter I entered a resident training program to become an internist. The past eighteen months I worked as a resident in internal medicine. 
Due to increasing interest in research I decided to interrupt my residency. During my PhD studies I will focus on phase I/II clinical trials. My main focus will be the REVIVAL study of carboplatin-olaparib in BRCAm breast cancer patients.

 

 

Close this window
Heinhuis, Kimberley

Kimberley Heinhuis

Ph.D. Student

Experience

I studied medicine at VUmc. In July 2015 I obtained my master's degree and started working as ANIOS oncology at the SLAZ hospital for 9 months. My project in The Netherlands cancer institute consists of phase I clinical studies with nivolumab in combination with newer therapies.

Close this window

Experience

Close this window
Huijberts, Sanne

Sanne Huijberts, MSc

Ph.D. Student

Experience

I finished medical school at the University of Amsterdam in january 2014. Hereafter I worked for 1 year as a resident in internal medicine at the AvL/NKI and for 8 months in Spaarne hospital. Due to my work in the clinic I became more and more interested in research, especially in oncology. I focus on phase I studies related to targeted therapy for BRAF mutated tumors.

Close this window
silhouette_geen_foto_thumb_man.jpg

Dick Pluim, BSc

Technician

Experience

I am involved as an independent researcher in the development and validation of non-invasive predictive and pharmacodynamic biomarker assays for monitoring the effect of molecular targeted anticancer agents. These assays can be used to predict if a patient will benefit from a particular treatment. This work includes: 1. enzymatic activity assays for dihydropyrimidine dehydrogenase, thymidine synthase, and polyADPribose polymerase. 2. assays for the enumeration of circulating epithelial and melanoma tumor cells.

 

 

Close this window
Ros.jpg

Willeke Ros, MSc

Ph.D. Student

Experience

My name is Willeke Ros I have completed my bachelor in Biology and my master in Biomedical Sciences at Leiden University. During my studies I have performed various  internships focusing mostly on fundamental research questions. However, during my last internship at the University of Wisconsin-Madison, I did research which was part of clinical trials. I enjoyed the translational nature of the research and decided I wanted to continue doing clinical research. During my PhD studies I will focus on phase I/II clinical trials related to immunotherapy.

Close this window
Knikman, Jonathan

Jonathan Knikman

Ph.D. student

Experience

I finished my master in Pharmacy in April 2018 and shortly after started my PhD at the NKI-AVL. The main focus of my PhD will be improving the safety, feasibility and cost-effectiveness of genotype- and phenotype-directed individualized dosing of fluoropyrimidines.

Close this window

Key publications View All Publications

  • Upfront Genotyping of DPYD*2A to Individualize Fluoropyrimidine Therapy: A Safety and Cost Analysis

    (2015) J Clin Oncol. Nov 16. pii: JCO.2015.63.1325. [Epub ahead of print]

    Deenen MJ, Meulendijks D, Cats A, Sechterberger MK, Severens JL, Boot H, Smits PH, Rosing H, Mandigers CM, Soesan M, Beijnen JH, Schellens et al.

    Link to PubMed
  • Clinical relevance of DPYD variants c.1679T>G, c.1236G>A/HapB3, and c.1601G>A as predictors of severe fluoropyrimidine-associated toxicity: a systematic review and meta-analysis of individual patient data

    (2015) Lancet Oncol. Oct 21. pii: S1470-2045(15)00286-7. doi: 10.1016/S1470-2045(15)00286-7. [Epub ahead of print]

    Meulendijks D, Henricks LM, Sonke GS, Deenen MJ, Froehlich TK, Amstutz U, Largiadèr CR, Jennings BA, Marinaki AM, Sanderson JD, Kleibl et al.

    Link to PubMed
 
 

Recent publications View All Publications

  • Pharmacokinetics and excretion of 14C-omacetaxine in patients with advanced solid tumors

    (2016) Invest New Drugs. May 25. [Epub ahead of print]

    Nijenhuis CM, Hellriegel E, Beijnen JH, Hershock D, Huitema AD, Lucas L, Mergui-Roelvink M, Munteanu M, Rabinovich-Guilatt L, Robertson...

    Link to PubMed
  • Regulatory aspects of human radiolabeled mass balance studies in oncology: concise review

    (2016) Drug Metab Rev. May 17:1-15. [Epub ahead of print]

    Nijenhuis CM, Schellens JH, Beijnen JH.

    Link to PubMed
 

Contact

  • Office manager

    Thea Eggenhuizen

  • E-mail

    t.eggenhuizen@nki.nl

  • Telephone Number

    +31 20 512 2035

Eggenhuizen, Thea.jpg

Donate

'Support for our research to test new treatments in patients based on breakthroughs in the lab'.

Support us
Share this page